DDInter533 DDInter1678
A commonly used x-ray contrast medium. As diatrizoate meglumine and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in many types of human cancer. Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants. In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids. In May 2015, the FDA approved sirolimus for the treatment of patients with lymphangioleiomyomatosis. In November 2021, albumin-bound sirolimus for intravenous injection was approved by the FDA for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumour (PEComa). Sirolimus was also investigated in other cancers such as skin cancer, Kaposi’s Sarcoma, cutaneous T-cell lymphomas, and tuberous sclerosis. The topical formulation of sirolimus, marketed as HYFTOR, was approved by the FDA in April 2022: this marks the first topical treatment approved in the US for facial angiofibroma associated with tuberous sclerosis complex.
Diatrizoate {u} (Compound) causes {v} (Side Effect) Haemoglobin
Haemoglobin {u} (Side Effect) is caused by {v} (Compound) Sirolimus
Diatrizoate {u} (Compound) causes {v} (Side Effect) Haemoglobin
Haemoglobin {u} (Side Effect) is caused by {v} (Compound) Tacrolimus
Tacrolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Diatrizoate {u} (Compound) causes {v} (Side Effect) Nephrotic syndrome
Nephrotic syndrome {u} (Side Effect) is caused by {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Diatrizoate {u} (Compound) resembles {v} (Compound) Metrizamide
Metrizamide {u} (Compound) upregulates {v} (Gene) PRKCQ
PRKCQ {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Diatrizoate {u} (Compound) causes {v} (Side Effect) Nephropathy
Nephropathy {u} (Side Effect) is caused by {v} (Compound) Mycophenolic acid
Mycophenolic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Diatrizoate {u} (Compound) resembles {v} (Compound) Iodipamide
Iodipamide {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Sirolimus
Diatrizoate {u} (Compound) resembles {v} (Compound) Metrizamide
Metrizamide {u} (Compound) downregulates {v} (Gene) GMPR2
GMPR2 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Diatrizoate {u} (Compound) is included by {v} (Pharmacologic Class) X-Ray Contrast Activity
X-Ray Contrast Activity {u} (Pharmacologic Class) includes {v} (Compound) Iohexol
Iohexol {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Diatrizoate {u} (Compound) resembles {v} (Compound) Metrizamide
Metrizamide {u} (Compound) downregulates {v} (Gene) SLC25A13
SLC25A13 {u} (Gene) is downregulated by {v} (Compound) Sirolimus
Diatrizoate {u} (Compound) causes {v} (Side Effect) Uremia
Uremia {u} (Side Effect) is caused by {v} (Compound) Pamidronic acid
Pamidronic acid {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Diatrizoate (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Sirolimus (Compound)
Diatrizoate (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Tacrolimus (Compound) and Tacrolimus (Compound) resembles Sirolimus (Compound)
Diatrizoate (Compound) causes Nephrotic syndrome (Side Effect) and Nephrotic syndrome (Side Effect) is caused by Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Diatrizoate (Compound) resembles Metrizamide (Compound) and Metrizamide (Compound) upregulates PRKCQ (Gene) and PRKCQ (Gene) is upregulated by Sirolimus (Compound)
Diatrizoate (Compound) causes Nephropathy (Side Effect) and Nephropathy (Side Effect) is caused by Mycophenolic acid (Compound) and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Diatrizoate (Compound) resembles Iodipamide (Compound) and Iodipamide (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Sirolimus (Compound)
Diatrizoate (Compound) resembles Metrizamide (Compound) and Metrizamide (Compound) downregulates GMPR2 (Gene) and GMPR2 (Gene) is upregulated by Sirolimus (Compound)
Diatrizoate (Compound) is included by X-Ray Contrast Activity (Pharmacologic Class) and X-Ray Contrast Activity (Pharmacologic Class) includes Iohexol (Compound) and Iohexol may lead to a major life threatening interaction when taken with Sirolimus
Diatrizoate (Compound) resembles Metrizamide (Compound) and Metrizamide (Compound) downregulates SLC25A13 (Gene) and SLC25A13 (Gene) is downregulated by Sirolimus (Compound)
Diatrizoate (Compound) causes Uremia (Side Effect) and Uremia (Side Effect) is caused by Pamidronic acid (Compound) and Pamidronic acid may lead to a major life threatening interaction when taken with Sirolimus